178 related articles for article (PubMed ID: 34680324)
21. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
22. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
Liu LL; Zhang SW; Chao X; Wang CH; Yang X; Zhang XK; Wen YL; Yun JP; Luo RZ
Cancer Immunol Immunother; 2021 Feb; 70(2):417-429. PubMed ID: 32770259
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Zhao Y; Zhang M; Pu H; Guo S; Zhang S; Wang Y
Front Oncol; 2020; 10():585961. PubMed ID: 33552963
[TBL] [Abstract][Full Text] [Related]
25. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
Chen L; Yang QC; Li YC; Yang LL; Liu JF; Li H; Xiao Y; Bu LL; Zhang WF; Sun ZJ
Cancer Immunol Res; 2020 Feb; 8(2):179-191. PubMed ID: 31771985
[TBL] [Abstract][Full Text] [Related]
26. CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT.
Xiao M; Duhem C; Chammout A; Berchem G; Janji B
J Cell Biochem; 2022 Jun; 123(6):1025-1031. PubMed ID: 35575054
[TBL] [Abstract][Full Text] [Related]
27. Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response.
Becker AS; Kluge C; Schofeld C; Zimpfer AH; Schneider B; Strüder D; Redwanz C; Ribbat-Idel J; Idel C; Maletzki C
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067301
[TBL] [Abstract][Full Text] [Related]
28. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
[TBL] [Abstract][Full Text] [Related]
29. CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.
Huang X; Liu W; Liu C; Hu J; Wang B; Ren A; Huang X; Yuan Y; Liu J; Li M
Front Mol Biosci; 2022; 9():983410. PubMed ID: 36589225
[No Abstract] [Full Text] [Related]
30. Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer.
Ubukata Y; Ogata K; Sohda M; Yokobori T; Shimoda Y; Handa T; Nakazawa N; Kimura A; Kogure N; Sano A; Sakai M; Ogawa H; Kuwano H; Shirabe K; Oyama T; Saeki H
Oncology; 2021; 99(1):15-22. PubMed ID: 33113541
[TBL] [Abstract][Full Text] [Related]
31. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
Yaseen MM; Abuharfeil NM; Darmani H
Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
[TBL] [Abstract][Full Text] [Related]
32. CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer.
Dai F; Duan YL; Feng Q; Song SL; Yang JL; Lv T
J Cancer; 2024; 15(8):2373-2379. PubMed ID: 38495487
[TBL] [Abstract][Full Text] [Related]
33. Chemokine-like factor-like MARVEL transmembrane domain containing 6: Bioinformatics and experiments
Meng H; Li S; Li Q; Wang Y; Wang G; Qu Y
Front Mol Neurosci; 2022; 15():1026927. PubMed ID: 36698778
[TBL] [Abstract][Full Text] [Related]
34. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence.
Muranushi R; Araki K; Yokobori T; Chingunjav B; Hoshino K; Dolgormaa G; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Harimoto N; Shimoda Y; Sano R; Oyama T; Saeki H; Shirabe K
Cancer Sci; 2021 Aug; 112(8):3314-3323. PubMed ID: 34080242
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.
Schlößer HA; Drebber U; Kloth M; Thelen M; Rothschild SI; Haase S; Garcia-Marquez M; Wennhold K; Berlth F; Urbanski A; Alakus H; Schauss A; Shimabukuro-Vornhagen A; Theurich S; Warnecke-Ebertz U; Stippel DL; Zippelius A; Büttner R; Hallek M; Hölscher AH; Zander T; Mönig SP; von Bergwelt-Baildon M
Oncoimmunology; 2016 May; 5(5):e1100789. PubMed ID: 27467911
[TBL] [Abstract][Full Text] [Related]
36. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
37. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
38. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.
Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W
EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308
[TBL] [Abstract][Full Text] [Related]
39. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
40. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
